Ruxolitinib cream side effects and safety information
Reviewed by Dr [PLACEHOLDER], dermatologist · Last reviewed [PLACEHOLDER date]
Read this before you start. It is based on the prescribing information for the original product, Opzelura (revised 06/2026). Rutinib contains the same active ingredient, so the same warnings apply.
WARNING: Serious infections, mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis
Serious infections
[PLACEHOLDER: paste exact label wording regarding risk of active tuberculosis, invasive fungal, viral, or opportunistic pathogens leading to hospitalization or death].
Mortality
[PLACEHOLDER: paste exact label wording regarding higher rate of all-cause mortality observed in patients 50 and older with CV risk factors treated with oral JAK inhibitors].
Malignancies
[PLACEHOLDER: paste exact label wording regarding lymphomas, non-melanoma skin cancers, and other solid malignancies reported with oral JAK inhibitors].
Major Adverse Cardiovascular Events (MACE)
[PLACEHOLDER: paste exact label wording regarding cardiovascular death, myocardial infarction, and stroke risks observed in related trials].
Thrombosis
[PLACEHOLDER: paste exact label wording regarding deep venous thrombosis, pulmonary embolism, and arterial thrombosis].
Who should not use it, or should talk to a doctor first
Ruxolitinib is a selective Janus kinase inhibitor. Systemic absorption occurs through topical use. Complete safety evaluation is required before commencing application.
- People who are immunocompromised. or undergoing active systemic chemotherapy.
- People using biological medicines. , other oral or topical JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine.
- People with an active serious infection. , past untreated tuberculosis, or persistent hepatitis B or C [PLACEHOLDER: confirm wording].
- Anyone pregnant or planning pregnancy. without dedicated obstetric evaluation.
- Breastfeeding individuals. (the official drug label explicitly advises avoiding breastfeeding during active therapy and for roughly four weeks post-final application).
Common side effects
The following adverse events were documented across double-blind, vehicle-controlled clinical studies in patients treated for atopic dermatitis and non-segmental vitiligo.
| Side effect | How common (from trials) |
|---|---|
| Nasopharyngitis (common cold) | [PLACEHOLDER from label] |
| Bronchitis | [PLACEHOLDER from label] |
| Ear infection | [PLACEHOLDER from label] |
| Eosinophil count increased | [PLACEHOLDER from label] |
| Urticaria (hives) | [PLACEHOLDER from label] |
| Folliculitis | [PLACEHOLDER from label] |
When to get urgent medical help
Signs [PLACEHOLDER: from patient information: e.g. acute signs of serious systemic infection, sudden chest pain, unexpected shortness of breath, localized calf warmth and leg swelling, or facial paralysis].
If you experience sudden, severe symptoms, cease cream application immediately and present to the nearest hospital emergency department or consult your treating physician without delay.
Using it safely
- Do not use more than the maximum amount. Adhere strictly to the recommended weekly dosage limit (e.g., 60 grams per week or 100 grams per 3 to 4 weeks, as defined by prescription). Do not apply over greater than 20% of total body surface area.
- Do not cover with dressings. Avoid occlusive bandages, wraps, or airtight plasters over treated lesions unless directed by a dermatologist, as occlusion drastically elevates systemic bloodstream absorption.
- Wash hands after applying. Clean hands thoroughly with soap and water immediately post-application, unless the hands themselves are the intended clinical treatment target site.
- Keep away from eyes, mouth and inside the nose. [PLACEHOLDER: confirm mucus membrane precautionary directives]. Rinse meticulously with saline or clean water if unintended contact occurs.
- Tell every doctor you see that you use it. Ensure all healthcare practitioners, including dentists and anaesthetists, note that you are applying an active topical JAK inhibitor prior to undergoing procedures or starting new prescriptions.
Report a side effect
If you think the cream caused a side effect, tell your doctor and report it to your national medicines regulator. You can also tell us at [PLACEHOLDER email] so we can pass it to the manufacturer.
Timely adverse incident reporting contributes to cumulative global safety registries and post-market safety oversight.
Have questions about safety or supply?
Tell us your country and we will tell you honestly whether we can supply it, what it costs and what paperwork you need.
References & Regulatory Sources
- Opzelura (ruxolitinib) cream 1.5% full prescribing information, revised 06/2026. U.S. Food and Drug Administration.
- Rutinib (ruxolitinib 1.5%) package leaflet and regulatory dossier [PLACEHOLDER].
On This Page
- Boxed warning
- Who should not use it
- Common side effects
- When to get medical help
- Using it safely
- Report a side effect
- Sources
Check availability and price →
Several of these warnings come from studies of JAK-inhibitor tablets. They appear on the cream’s label because it is the same class of medicine. Ask your doctor what they mean for you.
[1] Opzelura full prescribing information, revised 06/2026.
[2] Rutinib package leaflet [PLACEHOLDER].